Novo Nordisk (NOVO B) reported its Q2 2026 results on August 4, 2026, before the market open. The company reported earnings per share (EPS) of 6.18 DKK, beating the analyst estimate of 5.03 DKK by 22.9%. Revenue reached 78,488 million DKK. Following the release, the stock price rose by 1.75%.
Generated automatically from our data — as of August 12, 2026
Key figures at a glance
Estimate (EPS): 5.03 DKK
Reported (EPS): 6.18 DKK
Price reaction: +1.8%
Frequently asked questions
Did Novo Nordisk beat or miss earnings-per-share expectations?
Novo Nordisk beat the analyst estimate of 5.03 DKK earnings per share (Q2 2026) by 22.9%, reporting 6.18 DKK.
How did Novo Nordisk stock react to the earnings report?
Novo Nordisk stock rose 1.8% on the trading day following the release.
What was Novo Nordisk's revenue in Q2 2026?
Novo Nordisk reported revenue of 78,488M DKK in Q2 2026.